Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-15 + Docetaxel in Advanced NSCLC
NCT00051571Phase 2Completed
- Sponsor
- Seagen Inc.
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of SGN-15 in non-small cell lung carcinoma (NSCLC) (2 arms), sponsored by Seagen Inc. Primary endpoints: Tumor Response, Quality of Life and 1 more. Status: completed.
02
Drugs
SGN-15
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00051571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051571.